Amgen and UCB resubmit BLA for EVENITY to transform osteoporosis treatment in postmenopausal women

Amgen, in collaboration with UCB, has announced the resubmission of the biologics license application (BLA) for their osteoporosis drug candidate, EVENITY (romosozumab), to the US ... Read More